Epitope mapping of recombinant human gamma interferon using monoclonal antibodies. 1989

C Favre, and J Wijdenes, and H Cabrillat, and O Djossou, and J Banchereau, and J E de Vries
UNICET, Laboratory for Immunological Research, Dardilly, France.

Five monoclonal antibodies (MAbs B22, B27, 3-6, 32 and 35) specific for human recombinant IFN-gamma were characterized. These MAbs were used to set up quantitative sandwich ELISAs which allowed the detection of 1.25 ng/ml of IFN-gamma when diluted in normal human serum. Epitope mapping of the IFN-gamma molecule using these MAbs demonstrated that antibodies 3-6 and 32 which did not inhibit the biological activity of IFN-gamma recognized an epitope localized on the 15 C-terminal amino acids, suggesting that this portion of the molecule was not implicated in the biological activity of IFN-gamma. Sandwich ELISAs were performed using various pairs of MAbs. The level of reactivity obtained when antibodies B22 and B27 were used simultaneously as catcher and tracer was similar to the result obtained with two antibodies recognizing different epitopes. These results confirm that the IFN-gamma molecule is a dimer in solution and indicate that the two sites of the IFN-gamma dimeric molecule which are associated with the biological activity (epitope B22/B27) are fully exposed. In contrast, the C-terminus is only partially accessible to the antibodies 3-6/32, suggesting that the dimerization of IFN-gamma molecule results in the interaction of regions of the monomers that are homologous and adjacent to the C-terminus.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

C Favre, and J Wijdenes, and H Cabrillat, and O Djossou, and J Banchereau, and J E de Vries
January 1986, Ciba Foundation symposium,
C Favre, and J Wijdenes, and H Cabrillat, and O Djossou, and J Banchereau, and J E de Vries
September 2016, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
C Favre, and J Wijdenes, and H Cabrillat, and O Djossou, and J Banchereau, and J E de Vries
November 2017, Asian Pacific journal of cancer prevention : APJCP,
C Favre, and J Wijdenes, and H Cabrillat, and O Djossou, and J Banchereau, and J E de Vries
October 1988, Endocrinology,
C Favre, and J Wijdenes, and H Cabrillat, and O Djossou, and J Banchereau, and J E de Vries
January 2001, Archives of virology,
C Favre, and J Wijdenes, and H Cabrillat, and O Djossou, and J Banchereau, and J E de Vries
January 1995, Methods in molecular biology (Clifton, N.J.),
C Favre, and J Wijdenes, and H Cabrillat, and O Djossou, and J Banchereau, and J E de Vries
June 1994, Thrombosis and haemostasis,
C Favre, and J Wijdenes, and H Cabrillat, and O Djossou, and J Banchereau, and J E de Vries
January 1992, Autoimmunity,
C Favre, and J Wijdenes, and H Cabrillat, and O Djossou, and J Banchereau, and J E de Vries
January 1996, Virus genes,
C Favre, and J Wijdenes, and H Cabrillat, and O Djossou, and J Banchereau, and J E de Vries
January 1993, European journal of biochemistry,
Copied contents to your clipboard!